Moderna’s Covid-19 vaccine sales forecast slashed amidst strong competition
Pharmaceutical Technology
JANUARY 25, 2023
Despite this, Spikevax’s average annual sales forecast has plummeted by 23% between H1 and H2 2022 according to GlobalData’s Coronavirus Disease 2019 (COVID-19) Sector Forecast reports, due to increasing competition from Pfizer’s Comirnaty, Novavax’s Nuvaxovid, and Covid-19 therapeutics.
Let's personalize your content